Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReMEDy2 trial of DM199 for acute ischemic stroke
2024-513911-28-00Phase 3Authorised
- Sponsor
- DiaMedica Therapeutics
- Start
- Mar 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing DM199 with Placebo (2 arms). Primary endpoints: Excellent functional outcome at Day 90, Adverse events and serious adverse events and 6 more. Planned start Mar 2026; status: authorised.
02
Drugs
rinvecalinase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-513911-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513911-28-00.